Vivos Therapeutics, Inc. (VVOS): Total Liabilities
$26.70M
As of 2025-12-31
$28.13M
As of 2026-06-30
+44.1%
3-year compound annual growth
+26.0%
5-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $26.70M | +264.3% | 2026-04-15, Balance as of period end |
| 2024-12-31 | $7.33M | -29.0% | 2026-04-15, Balance as of period end |
| 2023-12-31 | $10.32M | +15.7% | 2025-03-31, Balance as of period end |
| 2022-12-31 | $8.92M | +9.4% | 2024-07-30, Balance as of period end |
| 2021-12-31 | $8.15M | -3.1% | 2023-03-30, Balance as of period end |
| 2020-12-31 | $8.41M | -8.4% | 2022-03-31, Balance as of period end |
| 2019-12-31 | $9.18M | n/a | 2021-03-25, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Vivos Therapeutics, Inc. (VVOS) | 2025-12-31 | $26.70M | +264.3% |
| Nephros Inc (NEPH) | 2025-12-31 | $3.44M | +31.0% |
| Profound Medical Corp. (PROF) | 2025-12-31 | $11.04M | +12.5% |
| Biotricity Inc. (BTCY) | 2026-03-31 | $39.41M | +10.5% |
| Sonoma Pharmaceuticals, Inc. (SNOA) | 2026-03-31 | $10.87M | +17.1% |
| Spectral AI, Inc. (MDAI) | 2025-12-31 | $27.13M | +40.2% |
| Allurion Technologies, Inc. (ALUR) | 2025-12-31 | $92.96M | -16.1% |
| Baird Medical Investment Holdings Ltd (BDMD) | 2025-12-31 | $38.48M | +0.7% |
| Nexgel, Inc. (NXGL) | 2025-12-31 | $5.57M | +13.6% |
Compare VVOS, NEPH, PROF, BTCY side by side · Screen every company in Surgical & Medical Instruments & Apparatus ↗